Bacterias for Energy: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
Line 43: Line 43:
**the board is used "to help evaluate and target research and development efforts for products"
**the board is used "to help evaluate and target research and development efforts for products"
**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
*"NanoLogix originally developed the patented intellectual property incorporated as a basis for **Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium."
**"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee.  Revenue has started from this arrangement."
http://www.tecnica.com/


=Bibliography=
=Bibliography=

Revision as of 11:12, 17 August 2009

The issue

Brief Outline of Research Results

Bacteria for Energy

A brief look at IP development at NanoLogix

  • commercialization of technologies including:
    • the production of bacteria
    • disease testing kits
  • "NanoLogix originally developed the patented intellectual property incorporated as a basis for **Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium."
    • "NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement."

http://www.tecnica.com/

Bibliography

Navigation=

Back to Biotechnology_-_Genomic_and_Proteomics